Three BriaCell posters and one publish-only abstract highlight robust clinical data from Bria-IMT™ and Bria-OTS™ ...
Bria-OTS has cleared its safety evaluation in the Phase 1/2 study monotherapy dosage setting Phase ...
Phase 2 survival and clinical benefit data meet or exceed outcomes of FDA-approved therapies in ...
Repeated positive recommendation from Data Safety Monitoring Board (“DSMB”) of pivotal Phase 3 study for ...
Phase 3 clinical data shows potential predictive biomarkers for treatment response, first identified in Phase ...
PHILADELPHIA and VANCOUVER, British Columbia, April 28, 2025 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: ...
Overall survival and clinical benefit in Phase 2 continue to outperform historical benchmarks, including very ...
PHILADELPHIA and VANCOUVER, British Columbia, April 24, 2025 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: ...
(IMAGES BELOW) Complete resolution of lung metastasis confirmed at 4 month follow-up in hormone receptor ...
PHILADELPHIA and VANCOUVER, British Columbia, April 23, 2025 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: ...
Accessibility Tools
